BridgeMD
New treatment option for Lung Cancers
Official title An Evaluation of Dose-escalation for Intrathoracic Tumours
ClinicalTrials.gov ID: NCT06794125
What this study is testing
- What it's testing
- This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause...
- Willingness and ability to provide informed consent
- Eastern Cooperative Oncology Group performance status 0-3
- Age 18 years or older
- Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist
You likely can't join if
- Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy...
- Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes...
- Pregnant or lactating women
- Inability to attend the full course of radiotherapy or planned follow-up visits
See the full eligibility criteria
- Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator)
- Willingness and ability to provide informed consent
- Eastern Cooperative Oncology Group performance status 0-3
- Age 18 years or older
- Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist
- Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist.
- Life expectancy greater than 3 months
- Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT...
- Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease.
- Pregnant or lactating women
- Inability to attend the full course of radiotherapy or planned follow-up visits
The study team makes the final eligibility decision.
Where it's taking place
- Kelowna, British Columbia, Canada
- London, Ontario, Canada
- Waterloo, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kelowna, British Columbia, Canada; London, Ontario, Canada; Waterloo, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.